Intellect Neurosciences Inc. (fka ILNS)

[itwillgetbetter]

I clearly understand the woring (WOULD INFRINGE).The patent milestone 2 million without question was and is past due without any doubt.

Pfizer nreached the contact.That a definite.

Thats not what I'm talking about.Ponezumab (Other Disease) is my point.It means if they use ponezumab for another diease lets say cancer and its FDA approved Intellect would receive royalities at the minimum most likely alot more then that.

The license contract just don't cover AD.It covers all other diseases ponezumab is used for.That way ILNS is compensated for whatever cure its used for.

I feel the ongoing trial is so closely related to A/D its fall under the current agreement milestones (royalties).It clearly shows Pfizer its defense did not stop the use of ponezumab and the attorneys lied in there filings and in court testimony.

Still say the definition of the onging trial puts it under A/D.
http://www.clinicaltrial.gov/ct2/show/NCT01821118?term=ponezumab&rank=5

http://www.nlm.nih.gov/medlineplus/ency/article/000719.htm

http://www.angiopathy.org/

My real question one after the payment for the breach of contract is made.

If Pfizers uses ponezumab for other diseases is it layed out in the license contract or do they negotiate another license for that disease or is it spelled out under the existing license contract?